## Takeji Umemura

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1430351/publications.pdf

Version: 2024-02-01

87888 91884 5,974 162 38 69 citations h-index g-index papers 165 165 165 5472 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	2â€Step PLT16â€AST44 method: Simplified liver fibrosis detection system in patients with nonâ€alcoholic fatty liver disease. Hepatology Research, 2022, 52, 352-363.	3.4	8
2	IL1R1 gene variants associate with disease susceptibility to IgG4-related periaortitis/periarteritis in IgG4-related disease. Gene, 2022, 820, 146212.	2.2	5
3	The levels of IL- $1\hat{l}^2$ and soluble IL-1 receptors in patients with IgG4-related periaortitis/periarteritis. Advances in Medical Sciences, 2022, 67, 257-261.	2.1	O
4	Serum thrombospondin 2 is a novel predictor for the severity in the patients with NAFLD. Liver International, 2021, 41, 505-514.	3.9	25
5	Primary Hepatic Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue in a Patient with Chronic Hepatitis B Virus Infection: Case Report and Summary of the Literature. Medicina (Lithuania), 2021, 57, 280.	2.0	3
6	Protocol: Prospective observational study investigating the prevalence and clinical outcome of portopulmonary hypertension in Japanese patients with chronic liver disease. PLoS ONE, 2021, 16, e0249435.	2.5	1
7	Quantitative and qualitative lipid improvement with chronic hepatitisÂC virus eradication using directâ€acting antivirals. Hepatology Research, 2021, 51, 758-766.	3.4	3
8	An Autopsy Case of Primary Biliary Cholangitis with Histological Submassive Hepatic Necrosis Caused by Acute Hepatitis E Virus Infection. Internal Medicine, 2021, 60, 1863-1870.	0.7	1
9	Investigation of the Effect of KIR–HLA Pairs on Hepatocellular Carcinoma in Hepatitis C Virus Cirrhotic Patients. Cancers, 2021, 13, 3267.	3.7	6
10	Successful treatment by glecaprevir/pibrentasvir followed by hepatoprotective therapy of acute chronic hepatitis exacerbation caused by daratumumab-based regimen for multiple myeloma: Case report and review of the literature. Journal of Infection and Chemotherapy, 2021, 27, 1750-1755.	1.7	3
11	aMAP score prediction of hepatocellular carcinoma occurrence and incidenceâ€free rate after a sustained virologic response in chronic hepatitis C. Hepatology Research, 2021, 51, 933-942.	3.4	15
12	I shall be released (from infinite HBV nucleos(t)ide analog therapy): Japanese experience. Journal of Hepatology, 2021, 75, 1496-1497.	3.7	1
13	Protocol: Prospective observational study aiming for micro-elimination of hepatitis C virus in Nagawa town: The Nagawa Project. PLoS ONE, 2021, 16, e0256711.	2.5	2
14	Association analysis of KIR/HLA genotype with liver cirrhosis, hepatocellular carcinoma, and NUC freedom in chronic hepatitis B patients. Scientific Reports, 2021, 11, 21424.	3.3	4
15	Role of G Protein-Coupled Receptors in Hepatic Stellate Cells and Approaches to Anti-Fibrotic Treatment of Non-Alcoholic Fatty Liver Disease. Frontiers in Endocrinology, 2021, 12, 773432.	3.5	12
16	Long-term luseogliflozin therapy improves histological activity of non-alcoholic steatohepatitis accompanied by type 2 diabetes mellitus. Clinical Journal of Gastroenterology, 2020, 13, 83-89.	0.8	7
17	Clinical utility of FibroScan as a nonâ€invasive diagnostic test for primary biliary cholangitis. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1208-1214.	2.8	17
18	Congestive hepatopathy and acute pancreatitis as severe complications of mixed connective tissue disease. Clinical Journal of Gastroenterology, 2020, 13, 434-442.	0.8	1

#	Article	IF	Citations
19	Polymorphism at rs9264942 is associated with HLA-C expression and inflammatory bowel disease in the Japanese. Scientific Reports, 2020, 10, 12424.	3.3	1
20	Clinical impact of normal alanine aminotransferase on directâ€acting antiviral outcome in patients with chronic hepatitis C virus infection. JGH Open, 2020, 4, 574-581.	1.6	3
21	Effectiveness of Glecaprevir/Pibrentasvir for Hepatitis C: Real-World Experience and Clinical Features of Retreatment Cases. Biomedicines, 2020, 8, 74.	3.2	11
22	Editorial: FAST score―a new predictive marker for HCC after SVR. Alimentary Pharmacology and Therapeutics, 2020, 52, 1222-1223.	3.7	2
23	A validation study of the Ursodeoxycholic Acid Response Score in Japanese patients with primary biliary cholangitis. Liver International, 2020, 40, 1926-1933.	3.9	14
24	A case of multiple hepatocellular carcinoma tumors with thoracic vertebra and adrenal gland metastases successfully treated with prolonged administration of reduced-dose regorafenib for more than 12 months. Acta Hepatologica Japonica, 2020, 61, 426-433.	0.1	1
25	POGLUT1, the putative effector gene driven by rs2293370 in primary biliary cholangitis susceptibility locus chromosome 3q13.33. Scientific Reports, 2019, 9, 102.	3.3	23
26	Biochemical and plasma lipid responses to pemafibrate in patients with primary biliary cholangitis. Hepatology Research, 2019, 49, 1236-1243.	3.4	24
27	Bezafibrate Improves GLOBE and UKâ€PBC Scores and Longâ€Term Outcomes in Patients With Primary Biliary Cholangitis. Hepatology, 2019, 70, 2035-2046.	7.3	83
28	KIR/HLA genotypes confer susceptibility and progression in patients with autoimmune hepatitis. JHEP Reports, 2019, 1, 353-360.	4.9	16
29	Renal impairment is associated with increased risk of mortality in patients with cirrhosis. Medicine (United States), 2019, 98, e14475.	1.0	9
30	Emergence of anti-mitochondrial M2 antibody in patient with angioimmunoblastic T-cell lymphoma. Clinical Journal of Gastroenterology, 2018, $11$ , $302-308$ .	0.8	2
31	Clinical features of autoimmune hepatitis with acute presentation: a Japanese nationwide survey. Journal of Gastroenterology, 2018, 53, 1079-1088.	5.1	35
32	A case of liver abscess co-infected with Desulfovibrio desulfuricans and Escherichia coli and review of the literature. Journal of Infection and Chemotherapy, 2018, 24, 393-397.	1.7	4
33	A case of hepatocellular carcinoma with iliac metastasis achieving complete long-term remission by multidisciplinary therapy with radiation therapy, transcatheter arterial chemoembolization, and sorafenib. Acta Hepatologica Japonica, 2018, 59, 117-124.	0.1	0
34	Genetics and epigenetics in the pathogenesis of primary biliary cholangitis. Clinical Journal of Gastroenterology, $2018, 11, 11-18$ .	0.8	36
35	Serum autotaxin is a useful liver fibrosis marker in patients with chronic hepatitis B virus infection. Hepatology Research, 2018, 48, 275-285.	3.4	34
36	Quantitative analysis of serum chemokines associated with treatment failure of direct-acting antivirals in chronic hepatitis C. Cytokine, 2018, 111, 357-363.	3.2	4

#	Article	IF	Citations
37	Serum Autotaxin Is a Useful Disease Progression Marker in Patients with Primary Biliary Cholangitis. Scientific Reports, 2018, 8, 8159.	3.3	32
38	Association between KIR-HLA combination and ulcerative colitis and Crohn's disease in a Japanese population. PLoS ONE, 2018, 13, e0195778.	2.5	21
39	Miglitol attenuates nonâ€alcoholic steatohepatitis in diabetic patients. Hepatology Research, 2018, 48, 1092-1098.	3.4	13
40	Past history of hepatocellular carcinoma is an independent risk factor of treatment failure in patients with chronic hepatitis C virus infection receiving directâ€acting antivirals. Journal of Viral Hepatitis, 2018, 25, 1462-1471.	2.0	21
41	Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C. PLoS ONE, 2018, 13, e0195632.	2.5	13
42	A cis-eQTL of HLA-DPB1 Affects Susceptibility to Type 1 Autoimmune Hepatitis. Scientific Reports, 2018, 8, 11924.	3.3	22
43	KIR2DL2 combined with HLA-C1 confers risk of hepatitis C virus-related hepatocellular carcinoma in younger patients. Oncotarget, 2018, 9, 19650-19661.	1.8	11
44	Serum autotaxin levels are correlated with hepatic fibrosis and ballooning in patients with non-alcoholic fatty liver disease. World Journal of Gastroenterology, 2018, 24, 1239-1249.	3.3	39
45	Mild drinking habit is a risk factor for hepatocarcinogenesis in non-alcoholic fatty liver disease with advanced fibrosis. World Journal of Gastroenterology, 2018, 24, 1440-1450.	3.3	54
46	III. Management for reactivation of hepatitis B virus. The Journal of the Japanese Society of Internal Medicine, 2018, 107, 26-31.	0.0	1
47	Serum <scp><i>Wisteria floribunda</i></scp> agglutininâ€positive human Macâ€2 binding protein may predict liver fibrosis and progression to hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Hepatology Research, 2017, 47, 226-233.	3.4	42
48	Clinicopathological characteristics of nonâ€B nonâ€C hepatocellular carcinoma without past hepatitis B virus infection. Hepatology Research, 2017, 47, 405-418.	3.4	30
49	Genome-wide association studies identifyPRKCBas a novel genetic susceptibility locus for primary biliary cholangitis in the Japanese population. Human Molecular Genetics, 2017, 26, ddw406.	2.9	46
50	Association of Serum Autotaxin Levels with Liver Fibrosis in Patients with Chronic Hepatitis C. Scientific Reports, 2017, 7, 46705.	3.3	49
51	Association of autoimmune hepatitis with Src homology 2 adaptor protein 3 gene polymorphisms in Japanese patients. Journal of Human Genetics, 2017, 62, 963-967.	2.3	20
52	Cimetidine/lactulose therapy ameliorates erythropoietic protoporphyria-related liver injury. Clinical Journal of Gastroenterology, 2017, 10, 452-458.	0.8	9
53	Association between lower air pressure and the onset of ischemic colitis: a case–control study. European Journal of Gastroenterology and Hepatology, 2017, 29, 1071-1078.	1.6	7
54	Association between serum soluble <scp>CD</scp> 14 and <scp>IL</scp> â€8 levels and clinical outcome in primary biliary cholangitis. Liver International, 2017, 37, 897-905.	3.9	22

#	Article	IF	CITATIONS
55	Genetic Contribution to the Pathogenesis of Primary Biliary Cholangitis. Journal of Immunology Research, 2017, 2017, 1-6.	2.2	17
56	Association between endotoxemia and histological features of nonalcoholic fatty liver disease. World Journal of Gastroenterology, 2017, 23, 712.	3.3	36
57	Liver stiffnessâ€spleen sizeâ€toâ€platelet ratio risk score identifies esophageal varices in Japanese patients with chronic hepatitis C. Hepatology Research, 2016, 46, 884-889.	3.4	12
58	Controlled attenuation parameter is correlated with actual hepatic fat content in patients with nonâ€alcoholic fatty liver disease with noneâ€toâ€mild obesity and liver fibrosis. Hepatology Research, 2016, 46, 1019-1027.	3.4	35
59	Liver stiffness-spleen size-to-platelet ratio risk score detects esophageal varices in chronic liver disease. SpringerPlus, 2016, 5, 998.	1.2	15
60	Histopathology of IgG4-Related Autoimmune Hepatitis and IgG4-Related Hepatopathy in IgG4-Related Disease. Seminars in Liver Disease, 2016, 36, 229-241.	3.6	40
61	Geographic distribution and characteristics of genotype A hepatitis B virus infection in acute and chronic hepatitis B patients in Japan. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 180-189.	2.8	36
62	Immunogenetics of IgG4-Related AIP. Current Topics in Microbiology and Immunology, 2016, 401, 35-44.	1.1	9
63	Genetic Association of PTPN22 Polymorphisms with Autoimmune Hepatitis and Primary Biliary Cholangitis in Japan. Scientific Reports, 2016, 6, 29770.	3.3	27
64	Incidence and prevalence of autoimmune hepatitis in the Ueda area, <scp>Japan</scp> . Hepatology Research, 2016, 46, 878-883.	3.4	34
65	Mechanism of the development of nonalcoholic steatohepatitis after pancreaticoduodenectomy. BBA Clinical, 2015, 3, 168-174.	4.1	26
66	Serum Cell Death Biomarkers for Prediction of Liver Fibrosis and Poor Prognosis in Primary Biliary Cirrhosis. PLoS ONE, 2015, 10, e0131658.	2.5	24
67	Genetic factors affect the etiology, clinical characteristics and outcome of autoimmune hepatitis. Clinical Journal of Gastroenterology, 2015, 8, 360-366.	0.8	11
68	Steatogenesis in adult-onset type II citrullinemia is associated with down-regulation of PPARα. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 473-481.	3.8	57
69	Primary hepatocellular carcinoma in a patient with neurofibromatosis type I. Liver International, 2015, 35, 2057-2058.	3.9	2
70	Serum sodium concentration is associated with increased risk of mortality in patients with compensated liver cirrhosis. Hepatology Research, 2015, 45, 739-744.	3.4	24
71	Factors associated with the effect of interferonâ€Î± sequential therapy in order to discontinue nucleoside/nucleotide analog treatment in patients with chronic hepatitis B. Hepatology Research, 2015, 45, 1195-1202.	3.4	22
72	Diagnostic and clinical significance of Crohn's disease-specific anti-MZGP2 pancreatic antibodies by a novel ELISA. Clinica Chimica Acta, 2015, 441, 176-181.	1.1	23

#	Article	IF	Citations
73	Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infectious Diseases, The, 2015, 15, 645-653.	9.1	333
74	Serum Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein Level Predicts Liver Fibrosis and Prognosis in Primary Biliary Cirrhosis. American Journal of Gastroenterology, 2015, 110, 857-864.	0.4	115
75	Mutations of pre-core and basal core promoter before and after hepatitis B e antigen seroconversion. World Journal of Gastroenterology, 2015, 21, 541.	3.3	15
76	Human Leukocyte Antigen Class II Haplotypes Affect Clinical Characteristics and Progression of Type 1 Autoimmune Hepatitis in Japan. PLoS ONE, 2014, 9, e100565.	2.5	54
77	STAT4Gene Polymorphisms Are Associated with Susceptibility and ANA Status in Primary Biliary Cirrhosis. Disease Markers, 2014, 2014, 1-8.	1.3	15
78	AST/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary biliary cirrhosis. Journal of Hepatology, 2014, 61, 1443-1445.	3.7	32
79	Genetic polymorphism in <i><scp>IFNL4</scp></i> and response to pegylated interferonâ€Î± and ribavirin in Japanese chronic hepatitis C patients. Tissue Antigens, 2014, 83, 45-48.	1.0	10
80	Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 <scp>HCV</scp> infection: an openâ€label, phase 3 trial. Journal of Viral Hepatitis, 2014, 21, 762-768.	2.0	191
81	Characteristics and prediction of hepatitis <scp>B</scp> eâ€antigen negative hepatitis following seroconversion in patients with chronic hepatitis <scp>B</scp> . Hepatology Research, 2014, 44, E45-53.	3.4	2
82	Multicenter validation study of antiâ€programmed cell deathâ€1 antibody as a serological marker for type 1 autoimmune hepatitis. Hepatology Research, 2014, 44, 1299-1307.	3.4	15
83	Serum levels of interleukinâ€22 and hepatitis <scp>B</scp> coreâ€related antigen are associated with treatment response to entecavir therapy in chronic hepatitis <scp>B</scp> . Hepatology Research, 2014, 44, E172-80.	3.4	20
84	Laparoscopic findings of congenital hepatic fibrosis: A case report and review of the published work. Hepatology Research, 2014, 44, 818-824.	3.4	3
85	KIR3DL1-HLA-Bw4 combination and IL28B polymorphism predict response to Peg-IFN and ribavirin with and without telaprevir in chronic hepatitis C. Human Immunology, 2014, 75, 822-826.	2.4	11
86	Risk factors for long-term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults. Hepatology, 2014, 59, 89-97.	<b>7.</b> 3	86
87	A case of repeated liver injury induced by different herbal medicines containing the same components. Acta Hepatologica Japonica, 2014, 55, 214-220.	0.1	3
88	lgG4-Related Autoimmune Hepatitis. , 2014, , 137-143.		0
89	Association analysis of toll-like receptor 4 polymorphisms in Japanese primary biliary cirrhosis. Human Immunology, 2013, 74, 219-222.	2.4	6
90	Cutaneous sarcoidosis in a chronic hepatitis <scp>C</scp> patient receiving pegylated interferon and ribavirin therapy. Hepatology Research, 2013, 43, 801-807.	3.4	10

#	Article	lF	Citations
91	Liver Dysfunction and Thrombocytopenia Diagnosed as Intravascular Large B-cell Lymphoma Using a Timely and Accurate Transjugular Liver Biopsy. Internal Medicine, 2013, 52, 1903-1908.	0.7	16
92	KIR, HLA, and IL28B Variant Predict Response to Antiviral Therapy in Genotype 1 Chronic Hepatitis C Patients in Japan. PLoS ONE, 2013, 8, e83381.	2.5	17
93	A patient with liver cirrhosis stage hepatitis C having hepatocellular carcinoma and cervical cancer of the uterus treated by octreotide for chylous ascites. Acta Hepatologica Japonica, 2013, 54, 284-290.	0.1	3
94	Changes in the serum level of hepatitis B virus (HBV) surface antigen over the natural course of HBV infection. Journal of Gastroenterology, 2012, 47, 1006-1013.	5.1	11
95	Association of IL28B gene polymorphism with development of hepatocellular carcinoma in Japanese patients with chronic hepatitis C virus infection. Human Immunology, 2012, 73, 298-300.	2.4	38
96	Genome-wide Association Study Identifies TNFSF15 and POU2AF1 as Susceptibility Loci for Primary Biliary Cirrhosis in the Japanese Population. American Journal of Human Genetics, 2012, 91, 721-728.	6.2	251
97	Long-term outcome of Japanese patients with type 1 autoimmune hepatitis. Hepatology, 2012, 56, 668-676.	7.3	95
98	Clinical Characteristics of Young-Onset Ischemic Colitis. Digestive Diseases and Sciences, 2012, 57, 1652-1659.	2.3	39
99	Human leukocyte antigen class II molecules confer both susceptibility and progression in Japanese patients with primary biliary cirrhosis. Hepatology, 2012, 55, 506-511.	<b>7.</b> 3	73
100	Universal vaccination of hepatitis B virus vaccine. Acta Hepatologica Japonica, 2012, 53, 117-130.	0.1	3
101	Cytokine profiles affecting the pathogenesis of autoimmune hepatitis in Japanese patients. Hepatology Research, 2011, 41, 350-357.	3.4	19
102	Serum chemokine levels are associated with the outcome of pegylated interferon and ribavirin therapy in patients with chronic hepatitis C. Hepatology Research, 2011, 41, 587-593.	3.4	18
103	Early detection of interstitial pneumonia by monitoring KL $\hat{a}$ in a chronic hepatitis C patient undergoing pegylated interferon and ribavirin therapy. Hepatology Research, 2011, 41, 904-909.	3.4	3
104	Serum interleukin (IL)-10 and IL-12 levels and IL28B gene polymorphisms: pretreatment prediction of treatment failure in chronic hepatitis C. Antiviral Therapy, 2011, 16, 1073-1080.	1.0	30
105	Polymorphism in the <i>KCNA3 </i> Gene Is Associated with Susceptibility to Autoimmune Pancreatitis in the Japanese Population. Disease Markers, 2011, 31, 223-229.	1.3	44
106	A Case of Pyogenic Liver Abscess Infected with Fusobacterium necrophorum Depicted by Microscopy and Confirmed by Tissue Culture. Internal Medicine, 2011, 50, 1815-1819.	0.7	20
107	Clinical significance of immunoglobulin G4-associated autoimmune hepatitis. Journal of Gastroenterology, 2011, 46, 48-55.	5.1	113
108	Genetic background of autoimmune hepatitis in Japan. Journal of Gastroenterology, 2011, 46, 42-47.	5.1	25

#	Article	IF	Citations
109	Genetic polymorphisms in CTLA4 and SLC4A2 are differentially associated with the pathogenesis of primary biliary cirrhosis in Japanese patients. Journal of Gastroenterology, 2011, 46, 1203-1212.	5.1	32
110	Association of Serum Cytokine Levels With Treatment Response to Pegylated Interferon and Ribavirin Therapy in Genotype 1 Chronic Hepatitis C Patients. Journal of Infectious Diseases, 2011, 203, 1087-1095.	4.0	50
111	Polymorphism in the KCNA3 gene is associated with susceptibility to autoimmune pancreatitis in the Japanese population. Disease Markers, 2011, 31, 223-9.	1.3	22
112	A Patient with Advanced Hepatocellular Carcinoma Treated with Sorafenib Tosylate Showed Massive Tumor Lysis with Avoidance of Tumor Lysis syndrome. Internal Medicine, 2010, 49, 991-994.	0.7	29
113	Nonalcoholic fatty liver disease in Japanese junior high school students: its prevalence and relationship to lifestyle habits. Journal of Gastroenterology, 2010, 45, 666-672.	5.1	36
114	Fucosylated Fraction of Alpha-Fetoprotein as a Predictor of Prognosis in Patients with Hepatocellular Carcinoma After Curative Treatment. Digestive Diseases and Sciences, 2010, 55, 2095-2101.	2.3	17
115	Another cause of autoimmune hepatitis. Hepatology, 2010, 52, 389-390.	7.3	21
116	Serum Fragmented Cytokeratin 18 Levels Reflect the Histologic Activity Score of Nonalcoholic Fatty Liver Disease More Accurately Than Serum Alanine Aminotransferase Levels. Journal of Clinical Gastroenterology, 2010, 44, 440-447.	2.2	68
117	A2BP1 as a novel susceptible gene for primary biliary cirrhosis in Japanese patients. Human Immunology, 2010, 71, 520-524.	2.4	18
118	Association analysis of cytotoxic T-lymphocyte antigen 4 gene polymorphisms with primary biliary cirrhosis in Japanese patients. Journal of Hepatology, 2010, 53, 537-541.	3.7	38
119	Down-regulation of SREBP-1c is associated with the development of burned-out NASH. Journal of Hepatology, 2010, 53, 724-731.	3.7	89
120	Prevention of immunosuppressive therapy or chemotherapy-induced reactivation of hepatitis B virus infection: Joint report of the Intractable Liver Diseases Study Group of Japan and the Japanese Study Group of the Standard Antiviral Therapy for Viral Hepatitis. Acta Hepatologica Japonica, 2009, 50, 38-42.	0.1	66
121	Epidemiology of hepatocellular carcinoma in Japan. Journal of Gastroenterology, 2009, 44, 102-107.	5.1	181
122	Association analysis of Toll-like receptor 4 polymorphisms with autoimmune pancreatitis. Human Immunology, 2009, 70, 742-746.	2.4	28
123	A case of wellâ€differentiated cholangiolocellular carcinoma visualized with contrastâ€enhanced ultrasonography using Sonazoid. Hepatology Research, 2009, 39, 207-212.	3.4	20
124	A case of relapsed hepatocellular carcinoma successfully evaluated by contrast-enhanced ultrasonography using SonazoidTM. Acta Hepatologica Japonica, 2009, 50, 250-256.	0.1	1
125	Development from simple steatosis to liver cirrhosis and hepatocellular carcinoma: a 27-year follow-up case. Clinical Journal of Gastroenterology, 2008, 1, 116-121.	0.8	27
126	History and prevention of deÂnovo hepatitisÂB virus-related hepatitis in Japan and the world. Clinical Journal of Gastroenterology, 2008, 1, 83-86.	0.8	17

#	Article	IF	Citations
127	Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology, 2008, 48, 1753-1760.	7.3	129
128	Insulin resistance and hepatitis C virus: a case–control study of nonâ€obese, nonâ€olcoholic and nonâ€steatotic hepatitis virus carriers with persistently normal serum aminotransferase. Liver International, 2008, 28, 1104-1111.	3.9	19
129	<i>De novo</i> autoimmune hepatitis following livingâ€donor liver transplantation for primary biliary cirrhosis. Clinical Transplantation, 2008, 22, 385-390.	1.6	26
130	Association of cytotoxic T-lymphocyte antigen 4 gene polymorphisms with type 1 autoimmune hepatitis in Japanese. Hepatology Research, 2008, 38, 689-695.	3.4	30
131	Association of Autoimmune Pancreatitis With Cytotoxic T-lymphocyte Antigen 4 Gene Polymorphisms in Japanese Patients. American Journal of Gastroenterology, 2008, 103, 588-594.	0.4	122
132	Mortality Secondary to Fulminant Hepatic Failure in Patients with Prior Resolution of Hepatitis B Virus Infection in Japan. Clinical Infectious Diseases, 2008, 47, e52-e56.	5.8	132
133	A Novel Immunoglobulin-Immunoglobulin Interaction in Autoimmunity. PLoS ONE, 2008, 3, e1637.	2.5	86
134	IgG4-Related Sclerosing Cholangitis Should Be Included as an Exclusion Criterion for the Diagnosis of Primary Sclerosing Cholangitis. American Journal of Gastroenterology, 2007, 102, 691-692.	0.4	20
135	A genomewide DNA microsatellite association study of Japanese patients with autoimmune hepatitis type 1. Hepatology, 2007, 45, 384-390.	7.3	45
136	Immunoglobin G4-hepatopathy: Association of immunoglobin G4-bearing plasma cells in liver with autoimmune pancreatitis. Hepatology, 2007, 46, 463-471.	7.3	256
137	Anti-Helicobacter pylori seropositivity: influence on severity and treatment response in patients with chronic hepatitis C. Journal of Viral Hepatitis, 2007, 14, 48-54.	2.0	7
138	Lack of association between FCRL3 and Fc $\hat{l}^3$ RII polymorphisms in Japanese type 1 autoimmune hepatitis. Clinical Immunology, 2007, 122, 338-342.	3.2	14
139	Epidemiology of hepatocellular carcinoma in Japan. Hepatology Research, 2007, 37, S95-S100.	3.4	58
140	Sclerosing cholangitis associated with autoimmune pancreatitis. Hepatology Research, 2007, 37, S487-S495.	3.4	31
141	A case of primary hepatic actinomycosis with a presumed invasion to abdominal wall, diagnosed with image examinations by chance. Acta Hepatologica Japonica, 2007, 48, 553-558.	0.1	4
142	Severe Hepatic Injury Caused by Orlistat. American Journal of Medicine, 2006, 119, e7.	1.5	20
143	Fatal HBV Reactivation in a Subject with Anti-HBs and Anti-HBc. Internal Medicine, 2006, 45, 747-748.	0.7	45
144	Severe Alcoholic Hepatitis with Extremely High Neutrophil Count Successfully Treated by Granulocytapheresis. Internal Medicine, 2006, 45, 155-158.	0.7	11

#	Article	IF	Citations
145	Useful parameters for distinguishing nonalcoholic steatohepatitis with mild steatosis from cryptogenic chronic hepatitis in the Japanese population. Liver International, 2006, 26, 956-963.	3.9	26
146	Two critical genes (HLA-DRB1 and ABCF1)in the HLA region are associated with the susceptibility to autoimmune pancreatitis. Immunogenetics, 2006, 59, 45-52.	2.4	100
147	Fulminant hepatitis after allogenic bone marrow transplantation caused by reactivation of hepatitis B virus with gene mutations in the core promotor region. European Journal of Haematology, 2006, 77, 255-258.	2.2	32
148	Quantitative analysis of anti-hepatitis C virus antibody-secreting B cells in patients with chronic hepatitis C. Hepatology, 2006, 43, 91-99.	7.3	32
149	Patients with and without loss of hepatitis B virus DNA after hepatitis B e antigen seroconversion have different virological characteristics. Journal of Medical Virology, 2006, 78, 68-73.	5.0	13
150	SEN virus: epidemiology and characteristics of a transfusion-transmitted virus. Transfusion, 2005, 45, 1084-1088.	1.6	36
151	Hepatocellular carcinoma: Recent trends in Japan. Gastroenterology, 2004, 127, S17-S26.	1.3	275
152	Prevalence of SEN Viruses among Injection Drug Users in the San Francisco Bay Area. Journal of Infectious Diseases, 2003, 188, 13-18.	4.0	10
153	Clinical significance of SEN virus infection in patients on maintenance haemodialysis. Nephrology Dialysis Transplantation, 2003, 18, 348-352.	0.7	21
154	Investigation of SEN Virus Infection in Patients with Cryptogenic Acute Liver Failure, Hepatitisâ€Associated Aplastic Anemia, or Acute and Chronic Non–A–E Hepatitis. Journal of Infectious Diseases, 2003, 188, 1545-1552.	4.0	69
155	Observation of positive selection within hypervariable regions of a newly identified DNA virus (SEN) Tj ETQq $1\ 1$	0.784314 2.8	rgBT/Overlo
156	SEN virus: Response to interferon alfa and influence on the severity and treatment response of coexistent hepatitis C. Hepatology, 2002, 35, 953-959.	7.3	34
157	SEN virus infection and its relationship to transfusion-associated hepatitis. Hepatology, 2001, 33, 1303-1311.	7.3	142
158	Genomic and Molecular Evolutionary Analysis of a Newly Identified Infectious Agent (SEN Virus) and Its Relationship to the TT Virus Family. Journal of Infectious Diseases, 2001, 183, 359-367.	4.0	158
159	Association between SEN Virus Infection and Hepatitis C in Japan. Journal of Infectious Diseases, 2001, 184, 1246-1251.	4.0	41
160	Dynamics of SEN Virus Infection among Injection Drug Users. Journal of Infectious Diseases, 2001, 184, 1315-1319.	4.0	35
161	T cell repertoire in the liver of patients with primary biliary cirrhosis. Human Immunology, 2000, 61, 675-683.	2.4	15
162	T cell repertoire in the liver of patients with autoimmune hepatitis. Human Immunology, 1999, 60, 806-815.	2.4	22